Benutzerspezifische Werkzeuge

Multiples Myelom

MM: MOR202C101

A Phase I/IIa, Open-Label, Multicentre, Dose-Escalation Study to Evaluate the Safety and Preliminary Efficacy of the Human Anti-CD38 Antibody MOR03087 as Monotherapy and in Combination with Standard Therapy in Subjects with Relapsed or Refractory Multiple Myeloma.Mehr…